Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

NCT04511624 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Subjects

Interventions

DRUG: IBI112 dose1
DRUG: IBI112 dose2
DRUG: IBI112 dose3
DRUG: IBI112 dose4
DRUG: IBI112 dose5
DRUG: IBI112 dose6
DRUG: IBI112 dose7

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.